Severe everolimus-induced steatohepatis: A case report

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Schieren, Gisela ^a   Bölke, Edwin ^a   Scherer, Axel ^b   Raffel, Andreas ^a   Gerber, Peter Arne ^a   Kröpil, Patric ^a   Schott, Matthias ^a   Hamilton, Jackson ^c   Hayman, Anne ^d   Knoefel, Wolfram Trudo ^a   Budach, Wilfried ^a   Matuschek, Christiane ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Luisenhospital Aachen ^*  (Germany)

^c UNIVERSITY OF TEXAS   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; EVEROLIMUS; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; OCTREOTIDE; PENTETREOTIDE IN 111; PROTEIN; SIMVASTATIN; STREPTOZOCIN; TRIACYLGLYCEROL; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APLASIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DISTANT METASTASIS; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; ILEUM CANCER; INCISIONAL HERNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE; SIDE EFFECT; TOMOGRAPHY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WHOLE BODY SCINTISCANNING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; LIVER TUMOR; METABOLISM; NEUROENDOCRINE TUMOR; TREATMENT OUTCOME;

AGED; FATTY LIVER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; MALE; NEUROENDOCRINE TUMORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84879832771     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-22     Document Type: Article

References (14)

1. Cystatin C-a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients. Bolke E, Schieren G, Gripp S, Steinbach G, Peiper M, Orth K, Matuschek C, Pelzer M, Lammering G, Houben R, Antke C, Rump LC, Mota R, Gerber PA, Schuler P, Hoffmann TK, Rusnak E, Hermsen D, Budach W, Strahlenther Onkol 2011 187 191 201 10.1007/s00066-010-2203-5 21359659
2. Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Matuschek C, Bolke E, Nawatny J, Hoffmann TK, Peiper M, Orth K, Gerber PA, Rusnak E, Lammering G, Budach W, Strahlenther Onkol 2011 187 135 139 10.1007/s00066-010-2184-4 21336713
3. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells. Ori Y, Herman-Edelstein M, Zingerman B, Rozen-Zvi B, Gafter U, Malachi T, Gafter-Gvili A, Biomed Pharmacother 2012 66 409 413 10.1016/j.biopha.2012.06.001 22795807
4. Current and emerging targeted therapies for metastatic breast cancer. Perez EA, Spano JP, Cancer 2012 118 3014 3025 10.1002/cncr.26356 22006669
5. Breast cancer: blocking both driver and escape pathways improves outcomes. Rimawi MF, Osborne CK, Nat Rev Clin Oncol 2012 9 133 134 10.1038/nrclinonc.2012.9 22330685
6. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Oberg K, Curr Opin Oncol 2012 24 433 440 10.1097/CCO.0b013e328353d7ba 22510940
7. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Naraev BG, Strosberg JR, Halfdanarson TR, Oncology 2012 83 117 127 10.1159/000339539 22797357
8. Chemotherapy-resistant metastatic breast cancer. Marquette C, Nabell L, Curr Treat Options Oncol 2012 13 263 275 10.1007/s11864-012-0184-6 22528367
9. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group, Lancet 2011 378 2005 2012 10.1016/S0140-6736(11)61742-X 22119496
10. Everolimus for advanced pancreatic neuroendocrine tumors. Yao JC, Shah MH, Ito T, Lombard Bohas C, Wolin EM, van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, N Engl J Med 2011 364 514 523 10.1056/NEJMoa1009290 21306238
11. Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy. Kirova YM, Servois V, Chargari C, Amessis M, Zerbib M, Beuzeboc P, Invest New Drugs 2012 30 1241 1243 10.1007/s10637-010-9613-1 21153752
12. L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. Osawa Y, Kanamori H, Seki E, Hoshi M, Ohtaki H, Yasuda Y, Ito H, Suetsugu A, Nagaki M, Moriwaki H, Saito K, Seishima M, J Biol Chem 2011 286 34800 34808 10.1074/jbc.M111.235473 21841000
13. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M, Br J Pharmacol 2012 165 2325 2340 10.1111/j.1476-5381.2011.01716.x 22014210
14. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA, Science 2012 335 1638 1643 10.1126/science.1215135 22461615